Apart from the glucose-lowering effect, SGLT2 inhibitors reduce body weight, blood pressure and, more importantly, the risk of cardiovascular events, heart-failure hospitalizations, and the progression of renal diseases [5,6,8,20,21,22,23]. This evidence concerns the gene SLC5A2 and heart failure.